Latest & greatest articles for pregnancy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregnancy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregnancy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregnancy

61. Thrombocytopenia in Pregnancy

Thrombocytopenia in Pregnancy Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2019 American College of Obstetricians and Gynecologists

62. Nonobstetric Surgery During Pregnancy

Nonobstetric Surgery During Pregnancy Nonobstetric Surgery During Pregnancy - ACOG Menu ▼ Nonobstetric Surgery During Pregnancy Page Navigation ▼ INTERIM UPDATE Number 775 (Replaces Committee Opinion No. 696, April 2017) Committee on Obstetric Practice American Society of Anesthesiologists This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice and the American Society of Anesthesiologists. This document reflects emerging (...) Pregnancy ABSTRACT: The American College of Obstetricians and Gynecologists' Committee on Obstetric Practice acknowledges that the issue of nonobstetric surgery during pregnancy is an important concern for physicians who care for women. Because of the difficulty of conducting large-scale randomized clinical trials in this population, there are no data to allow for specific recommendations. It is important for a physician to obtain an obstetric consultation before performing nonobstetric surgery and some

2019 American College of Obstetricians and Gynecologists

63. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT)

Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) - Regan - - BJOG: An International Journal of Obstetrics & Gynaecology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term RCOG Scientific Impact Paper Free Access Prenatal Management of Pregnancies (...) , and as a consequence, reduced use of invasive fetal testing and fetal blood sampling (FBS). There is very little high quality evidence on which to base management of this condition, but advances in treatment report very good outcomes. Severe FNAIT is very rare, adverse consequences for the fetus are potentially disastrous and the treatments are costly. This document considers the latest evidence in relation to treatment options in the prenatal management of pregnancies at risk of FNAIT; specifically, the role

2019 Royal College of Obstetricians and Gynaecologists

64. Pregnancy and lower urinary tract infection: opt for cefuroxime

Pregnancy and lower urinary tract infection: opt for cefuroxime Prescrire IN ENGLISH - Spotlight ''Pregnancy and lower urinary tract infection: opt for cefuroxime'', 1 April 2019 {1} {1} {1} | | > > > Pregnancy and lower urinary tract infection: opt for cefuroxime Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Pregnancy and lower urinary tract (...) infection: opt for cefuroxime Requiring just a single dose, fosfomycin trometamol is easier to take than cefuroxime or the combination of amoxicillin + clavulanic acid, but less is known about its short-term effects on the unborn child exposed during the first trimester of pregnancy. It is wiser to choose cefuroxime as first-line treatment. Minor lower urinary tract infections are frequent during pregnancy. They are routinely treated because they are a risk factor for premature birth. The first-choice

2019 Prescrire

65. Immune Modulating Therapies in Pregnancy and Lactation

Immune Modulating Therapies in Pregnancy and Lactation Immune Modulating Therapies in Pregnancy and Lactation - ACOG Menu ▼ Immune Modulating Therapies in Pregnancy and Lactation Page Navigation ▼ Number 776 Committee on Obstetric Practice Society for Maternal-Fetal Medicine This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice in collaboration with committee member Alison G. Cahill, MD, MSCI, and the Society (...) by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product. Immune Modulating Therapies in Pregnancy and Lactation ABSTRACT: Because autoimmune conditions occur more often among women of childbearing age, continuation of these medications during pregnancy is often considered to optimize disease management in the woman and pregnancy outcomes, without placing

2019 American College of Obstetricians and Gynecologists

66. Support during pregnancy for women at increased risk of low birthweight babies. (PubMed)

Support during pregnancy for women at increased risk of low birthweight babies. Studies consistently show a relationship between social disadvantage and low birthweight. Many countries have programmes offering special assistance to women thought to be at risk for giving birth to a low birthweight infant. These programmes, collectively referred to in this review as additional social support, may include emotional support, which gives a person a feeling of being loved and cared for, tangible (...) , instrumental/tangible and informational) compared with routine care, for pregnant women believed to be at high risk for giving birth to babies that are either preterm (less than 37 weeks' gestation) or weigh less than 2500 g, or both, at birth. Secondary objectives were to determine whether the effectiveness of support was mediated by timing of onset (early versus later in pregnancy) or type of provider (healthcare professional or lay person).For this update, we searched Cochrane Pregnancy and Childbirth's

2019 Cochrane

67. 17alpha-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis

17alpha-Hydroxyprogesterone Caproate and the Risk of Glucose Intolerance in Pregnancy: A Systematic Review and Meta-analysis To evaluate whether 17α-hydroxyprogesterone caproate use in preventing preterm birth increases the risk of gestational diabetes mellitus (GDM).Electronic databases (MEDLINE, Scopus, ClinicalTrials.gov, PROSPERO, EMBASE, Scielo and the Cochrane Central Register of Controlled Trials) were searched for studies published before October 2018. Keywords included "gestational (...) diabetes," "preterm birth," "pregnancy," and "17-hydroxyprogesterone caproate."Studies comparing 17α-hydroxyprogesterone caproate with unexposed control groups in women with singleton gestation and a history of a prior spontaneous preterm birth were included. The primary outcome was the development of GDM. Secondary outcomes included abnormal 1-hour, 50-g glucose screen results and mean venous blood glucose levels. Summary estimates were reported as mean differences and 95% CI for continuous variables

2019 EvidenceUpdates

68. Pessary Compared With Vaginal Progesterone for the Prevention of Preterm Birth in Women With Twin Pregnancies and Cervical Length Less Than 38 mm: A Randomized Controlled Trial

Pessary Compared With Vaginal Progesterone for the Prevention of Preterm Birth in Women With Twin Pregnancies and Cervical Length Less Than 38 mm: A Randomized Controlled Trial To compare the effectiveness of cervical pessary to vaginal progesterone for the prevention of preterm birth in women with twin pregnancies and short cervix.This randomized controlled trial was conducted at My Duc Hospital, Vietnam. Asymptomatic women with twin pregnancies and cervical length less than 38 mm were (...) outcomes (19% vs 27%; RR 0.70, 95% CI 0.43-0.93). In women with cervical length of 28 mm or less (25th percentile), pessary significantly reduced the preterm birth rate at less than 34 weeks of gestation from 46% (16/35) to 21% (10/47) (RR 0.47, 95% CI 0.24-0.90) and significantly improved the composite of poor perinatal outcomes.Cervical pessary and 400 mg vaginal progesterone resulted in similar rates of preterm birth at less than 34 weeks of gestation in women with twin pregnancies and cervical

2019 EvidenceUpdates

69. Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies

Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies While topical azoles are the first-line treatment for fungal infections, oral fluconazole is frequently used during pregnancy. We aimed to assess the effect of exposure to low and high doses of fluconazole during pregnancy on the occurrence of spontaneous abortions, major congenital malformations and stillbirths.Within the Quebec Pregnancy Cohort (1998-2015), we identified women (...) to analyze the 3 main outcomes separately.Within a cohort of 441 949 pregnancies, 320 868 pregnancies were included in the analyses of spontaneous abortions, 226 599 of major congenital malformations and 7832 of stillbirths. Most (69.5%) women exposed to fluconazole in pregnancy received the common single therapeutic dose of 150 mg (low dose); the remainder received a dose of > 150 mg (high dose). Use of oral fluconazole during early pregnancy was associated with an increased risk of spontaneous abortion

Full Text available with Trip Pro

2019 EvidenceUpdates

70. Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme

Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme Valproate medicines and serious harms in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Valproate medicines and serious harms (...) in pregnancy: new Annual Risk Acknowledgement Form and clinical guidance from professional bodies to support compliance with the Pregnancy Prevention Programme Ongoing patient survey data suggest that more effort is needed by clinicians to achieve full and timely compliance with the valproate Pregnancy Prevention Programme and meet the goal to rapidly reduce and eventually eliminate the harms of valproate in pregnancy in view of its serious teratogenicity. We have updated the Annual Risk Acknowledgement

Full Text available with Trip Pro

2019 MHRA Drug Safety Update

71. Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1

Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 Pharmacokinetic data (...) indicate exposure of elvitegravir boosted with cobicistat (Genvoya▼, Stribild) is lower during the second and third trimesters of pregnancy than postpartum. Low elvitegravir exposure may be associated with an increased risk of treatment failure and an increased risk of HIV-1 transmission to the unborn child, and therefore elvitegravir/cobicistat should not be used during pregnancy. Published 16 April 2019 From: Therapeutic area: , , Contents Advice for healthcare professionals: pharmacokinetic data

2019 MHRA Drug Safety Update

72. Ectopic pregnancy and miscarriage: diagnosis and initial management

Ectopic pregnancy and miscarriage: diagnosis and initial management Ectopic pregnancy and miscarriage: Ectopic pregnancy and miscarriage: diagnosis and initial management diagnosis and initial management NICE guideline Published: 17 April 2019 nice.org.uk/guidance/ng126 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view (...) in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

73. Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed?

Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? New guidance on contraceptive methods and frequency of pregnancy testing to reduce inadvertent (...) exposures during pregnancy in a woman taking a medicine of teratogenic potential. Published 21 March 2019 From: Therapeutic area: , , Contents Background Some medicines are known or suspected to have the potential to increase the risk of birth defects and development disorders (teratogenic potential) when taken during pregnancy, especially during the first trimester (up to week 12 of pregnancy), when a woman may not know she is pregnant. The product information for these medicines advise that pregnancy

2019 MHRA Drug Safety Update

74. High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. (PubMed)

High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. 30860552 2019 03 25 2019 09 12 1538-3598 321 10 2019 03 12 JAMA JAMA High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. 1003-1005 10.1001/jama.2019.0052 Brustad Nicklas N Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Eliasen Anders U AU Copenhagen Prospective Studies on Asthma (...) Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. eng Journal Article Randomized Controlled Trial United States JAMA 7501160 0098-7484 0 Vitamins 1406-16-2 Vitamin D AIM IM Asthma diagnosis epidemiology prevention & control Child Child, Preschool Dietary Supplements Dose-Response Relationship, Drug Female Follow-Up Studies Humans Male Pregnancy Prevalence Regression Analysis Respiratory Function Tests Respiratory Sounds Vitamin D administration

2019 JAMA Controlled trial quality: uncertain

75. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. (PubMed)

Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Intrahepatic cholestasis of pregnancy is associated with adverse perinatal outcomes, but the association with the concentration of specific biochemical markers is unclear. We aimed to quantify the adverse perinatal effects of intrahepatic cholestasis of pregnancy in women with increased serum bile acid concentrations (...) and determine whether elevated bile acid concentrations were associated with the risk of stillbirth and preterm birth.We did a systematic review by searching PubMed, Web of Science, and Embase databases for studies published from database inception to June 1, 2018, reporting perinatal outcomes for women with intrahepatic cholestasis of pregnancy when serum bile acid concentrations were available. Inclusion criteria were studies defining intrahepatic cholestasis of pregnancy based upon pruritus and elevated

Full Text available with Trip Pro

2019 Lancet

76. Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. (PubMed)

Desmopressin acetate (DDAVP) for preventing and treating acute bleeds during pregnancy in women with congenital bleeding disorders. Congenital bleeding disorders can cause obstetric haemorrhage during pregnancy, labour and following delivery. Desmopressin acetate (DDAVP) is found to be an effective drug which can reduce the risk of haemorrhage and can also stop bleeding in certain congenital bleeding disorders. Its use in pregnancy has been controversial. Hence beneficial and adverse effects (...) of conferences proceedings. We also searched several clinical trial registries and grey literature (27 August 2017).Date of most recent search of the Cochrane Cystic Fibrosis and Genetic Disorders Group's Coaguopathies Trials Register: 01 October 2018.Randomised and quasi-randomised controlled trials investigating the efficacy of DDAVP versus tranexamic acid or factor VIII or rFactor VII or fresh frozen plasma in preventing and treating congenital bleeding disorders during pregnancy were eligible.No trials

2019 Cochrane

77. MRI during pregnancy: the pros and cons should be carefully assessed

MRI during pregnancy: the pros and cons should be carefully assessed Prescrire IN ENGLISH - Spotlight ''MRI during pregnancy: the pros and cons should be carefully assessed'', 1 February 2019 {1} {1} {1} | | > > > MRI during pregnancy: the pros and cons should be carefully assessed Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight MRI during (...) pregnancy: the pros and cons should be carefully assessed Before deciding to give a pregnant woman an MRI scan, with or without contrast agents, it is important to consider how the MRI results would change the clinical course. MRI, or magnetic resonance imaging, uses powerful electromagnetic fields that make tissues hot. In a study of 1500 children who had been exposed to MRI (without injection of a contrast agent) in the first trimester of pregnancy, vascular, digestive, musculoskeletal and auditory

2019 Prescrire

78. Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period

Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period INTERIM UPDATE ACOGCOMMITTEEOPINION Number 767 (Replaces Committee Opinion Number 692, September 2017) Committee on Obstetric Practice This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice in collaboration with committee members Yasser Y. El-Sayed, MD, and Ann E. Borders, MD, MSc, MPH. INTERIM UPDATE: This Committee Opinion (...) is updated as highlighted to align with the American College of Obstetricians and Gynecologists’ guidance on gestational hypertension, preeclampsia, and chronic hypertension in pregnancy. Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period ABSTRACT: Acute-onset, severe systolic hypertension; severe diastolic hypertension; or both can occur during the prenatal, intrapartum, or postpartum periods. Pregnant women or women in the postpartum period with acute-onset

2019 American College of Obstetricians and Gynecologists

79. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group

Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search To read this article in full, please review your options for gaining (...) access at the bottom of the page. Article in Press Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group x Uma Mahadevan Affiliations University of California, San Francisco, San Francisco, California 1 , x Christopher Robinson Affiliations Bon Secours St Francis and Summerville Medical Center, Charleston, South Carolina 2 , x Nana Bernasko Affiliations Penn State Health, Milton S. Hershey Medical

2019 American Gastroenterological Association Institute

80. HIV in pregnancy: Identification of intrapartum and perinatal HIV exposures

HIV in pregnancy: Identification of intrapartum and perinatal HIV exposures The benefits of human immunodeficiency virus (HIV) testing in pregnancy, when combined with appropriate maternal antiretroviral therapy and intrapartum and postnatal prophylaxis, are well established. The vertical rate of transmission of HIV in North America is now well below 2%. Efforts must continue to ensure that these benefits are sustained. Women who have received little or no prenatal care and those who present (...) for delivery with unknown HIV status need immediate testing. As more infants are exposed to antiretroviral agents, strategies need to be implemented to ensure adequate follow-up of these infants. Issues relating to the identification of HIV-exposed infants are highlighted. Keywords: Human immunodeficiency virus; Infant; Intrapartum transmission; Pregnancy; Screening

2019 Canadian Paediatric Society